Clinical trial
A Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line…
NCT00477711 · Peking University, Other · Completed
Key facts
| NCT number | NCT00477711 |
|---|---|
| Title | A Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric Cancer |
| Acronym | EXTRA |
| Lead sponsor | Peking University, Other |
| Collaborators | Merck Sharp & Dohme LLC Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastric Cancer |
| Intervention type | Drug |
| Interventions | cetuximab, cisplatin, capecitabine |
| Enrollment | 41 |
| Start date | Mar 1, 2007 |
| Primary completion | Dec 1, 2008 |
| Completion | Feb 1, 2009 |
| First posted | May 24, 2007 |
| Last update posted | May 19, 2015 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: